Overview

Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

Status:
Recruiting

Trial end date:
2024-01-01

Target enrollment:

Participant gender:

Summary

This is a Phase 3 open-label, multicenter, randomized, active-controlled study designed to compare the efficacy and safety and tolerability of P1101 compared with ANA after 12 months of treatment as second-line therapy for subjects with ET who have had a suboptimal or failed response to HU.

Phase:

Phase 3

Details

Lead Sponsor:

PharmaEssentia

Collaborators:

Brightech International
EPS International
Medpace, Inc.

Treatments:

Anagrelide